Researchers discover that moderate exercise following bariatric surgery reduces specific metabolic risk factors associated with type 2 diabetes. The findings suggest that moderate exercise may provide additional benefits to health beyond weight loss in these patients.
A team of Sanford-Burnham and Mayo Clinic researchers will work with GlaxoSmithKline to develop a novel treatment for resistant high blood pressure.
A $1-million gift will establish an international collaboration between Sanford-Burnham Medical Research Institute (Sanford-Burnham) and the Tanz Centre for Research in Neurodegenerative Diseases (Tanz Centre) at the University of Toronto to accelerate the development of new therapeutics to treat neurodegenerative diseases.
Sanford-Burnham Medical Research Institute at Lake Nona today announced it has recruited two cardiometabolic experts to its Medical City campus in Lake Nona.
Researchers discover the cell events in the brains of individuals with Down syndrome that lead to the amyloid pathology observed in the brains of patients with Alzheimer’s disease. The findings support a novel approach to treating and preventing both diseases.
Potential biomarkers may pave way to a more sensitive, specific, and non-invasive prostate cancer screening assay, according to report in The Journal of Molecular Diagnostics.
Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced the election of five new members to its Board of Trustees.
A new study finds that cyclic bursts of a STAT3 inhibitor can replenish muscle stem cells and promote their differentiation into muscle fibers. The findings are an important step toward developing and maintaining new muscle to treat muscle diseases.
Sanford-Burnham Medical Research Institute today announced that its Board of Trustees has appointed Perry Nisen, M.D., Ph.D., as Chief Executive Officer and holder of the Donald Bren Chief Executive Chair. In this role, he will lead the Institute and oversee the execution of its new 10-year strategic vision to more quickly translate basic research discoveries into novel treatments that improve human health.
Researchers discover a simple peptide that can induce new beta-cell formation in the pancreas. The findings show promise for a new approach to treating type 1 diabetes.
Study finds that the NBR1 protein plays a critical role in regulating obesity-induced inflammation that leads to metabolic disease. The findings suggest a new approach to targeting the inflammatory links between obesity and metabolic disease to prevent and treat type 2 diabetes.
Research identifies a mechanism in the tumor stroma that triggers an inflammatory response, promoting tumor growth and metastasis. The findings suggest a new approach to anti-cancer therapies that incorporates targets in the tumor microenvironment.
Study finds a modification to the transcriptional protein MEF2 that inhibits the growth of new brain cells and survival of existing cells. The findings show promise for therapeutic intervention for a variety of neurodegenerative disorders.
Study identifies two novel oncogenes that cause childhood brain cancer when activated.
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd., today announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases. The collaboration is built on an open-innovation model to bridge the gap between target discovery and pre-clinical drug development.
Study identifies a novel molecule that prevents the symptoms associated with allergen-induced asthma.
Study shows the first evidence that hyaluronic acid plays a role in epileptic seizures, providing a potential new approach for treatments.
Sanford-Burnham researchers discover that the interaction between two proteins called BCAR1 and BCAR3 is responsible for resistance to antiestrogen drugs, paving the way for improved diagnostic and treatment strategies.
Researchers reveal novel cellular and molecular elements of muscle repair. The study explains how drugs can induce regeneration, while preventing fibrosis and fat deposition, in dystrophic muscle at early stages of Duchenne muscular dystrophy.
Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors.
Researchers discover mutations in a protein that plays a role in the body’s DNA repair system—similar to what’s observed in the rare children’s disease ataxia-telangiectasia. The discovery provides an approach to identifying therapies that will resuscitate the broken DNA repair mechanism.
Sanford-Burnham Medical Research Institute (Sanford-Burnham) announced that Carol Cox joined the Institute as senior vice president of External Relations on March 4.
Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced that its Board of Trustees has approved a new 10-year strategic vision to accelerate the Institute’s impact on improving human health. The vision will fortify Sanford-Burnham’s leadership of an emerging 21st-century research model that encourages innovation by aligning basic biomedical research, translational research, and drug discovery and development.
A new study discovers a molecule termed "THRIL" that regulates TNF-alpha.
The study identifies the BTLA inhibitory receptor as a key factor in limiting inflammatory responses, particularly in skin. The research has important implications for psoriasis drug development. By targeting the BTLA receptor, inflammatory responses can be reined to restore immune homeostasis.
Study uses patient-derived stem cells to show that a mutation in the α-synuclein gene causes increased vulnerability to pesticides, leading to Parkinson’s disease.
A bicoastal group of scientists at Sanford-Burnham Medical Research Institute was recently awarded a three-year grant from the U.S. Department of the Air Force to assess the potential toxicity of large collections of chemicals. The goal of the project is to provide an early and relevant assessment of potential toxicities in a rapid, cost-effective manner.
Sanford-Burnham Medical Research Institute president and interim CEO, Kristiina Vuori, M.D., Ph.D., joined the advisory board of the Florida Inventors Hall of Fame at the University of South Florida in Tampa.
Sanford-Burnham Medical Research Institute announced the election of two new trustees to its Board of Trustees. The Board will grow to 24 members with the addition of William Gerhart, a San Diego, Calif.-based pharmaceutical pioneer, and Luder G. Whitlock, Jr., executive director of The CNL Charitable Foundation in Orlando, Fla.
A new experimental approach to treating a type of brain cancer called medulloblastoma has been developed by researchers at Sanford-Burnham Medical Research Institute.
Kristiina Vuori, M.D., Ph.D., president and interim CEO of Sanford-Burnham Medical Research Institute (Sanford-Burnham), has been named to the California Breast Cancer Research Council, the official advisory body for the California Breast Cancer Research Program (CBCRP).
Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced that its Board of Trustees has elected Gregory T. Lucier chairman of the Institute’s Board. Lucier is chairman and CEO of Life Technologies and will assume the role of Board chairman on September 18.
The PDK1 gene, known to regulate many cell functions such as metabolism and survival, is now identified as a key regulator in melanoma development and metastasis, offering new opportunities to interfere with cancer progression.
Sanford-Burnham Medical Research Institute staff and leaders are deeply saddened by the recent loss of Lillian Fishman, our co-founder and early guiding light. Lillian and her late husband, Dr. William Fishman, worked side-by-side for more than 45 years to advance biomedical research. Lillian passed away at her home in La Jolla on August 24. She was 98.
Collaboration utilizes Sanford-Burnham drug discovery platform to find new therapeutic targets for treating complications of obesity and diabetes
Scientists at Sanford-Burnham Medical Research Institute have identified a key factor that regulates the autophagy process, a kind of cleansing mechanism for cells in which waste material and cellular debris is gobbled up to protect cells from damage, and in turn, modulates aging.
Sanford-Burnham Medical Research Institute staff and leaders are extremely sad to hear of the passing of our friend and colleague, Duane Roth.
Researchers at Sanford-Burnham Medical Research Institute now have a more complete picture of one particular pathway that can lead to cancer and diabetes. In the study published by Molecular Cell, the scientists uncovered how a protein called p62 has a cascade affect in regulating cell growth in response to the presence of nutrients such as amino acids and glucose.
SMIP004 holds promise as a novel, much-needed treatment for advanced prostate cancer
NitroMemantine is the first drug to halt the progression of synaptic loss and to even restore these connections between nerve cells. The combination drug is now headed for clinical trials.
A collaboration of scientists at Sanford-Burnham and the University of California, Santa Barbara, finds that rod-shaped particles, rather than spherical particles, appear more effective at adhering to cells where they’re needed.
The gene Dkk1 encodes a protein that plays a key role in increasing the population of connective-tissue cells during wound repair, but prolonged Dkk1 signaling in cells lining blood vessels can lead to fibrosis and a stiffening of artery walls.
Sanford-Burnham Medical Research Institute at Lake Nona (Sanford-Burnham) announced the recruitment of the internationally renowned genomic scientist László Nagy, M.D., Ph.D., to serve as professor and program director in its Diabetes and Obesity Research Center.
Sanford-Burnham researchers identify microRNAs as the missing link between the two defining features of muscle fitness—fuel-burning and fiber-type switching—providing a potential new target for interventions that boost fitness in people with chronic illness or injury.
Unique computer model calculates how long a blood stem cell will live, information that could predict the outcome of bone marrow transplants.
New technique removes several hurdles in generating induced pluripotent stem (iPS) cells, smoothing the way for disease research and drug development.
Fruit fly study demonstrates how lipotoxic cardiomyopathy might occur in genetically obese individuals, revealing potential therapeutic targets for fat-related heart disease.
Sanford-Burnham Medical Research Institute has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer’s disease and major psychiatric disorders.
Florida Hospital, Sanford-Burnham Medical Research Institute and Takeda Pharmaceutical Company have signed a research agreement to discover and evaluate new therapeutic approaches to obesity.
Protein required for early stages of melanoma development can also predict melanoma outcome.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right